Ping An Life launches the industry’s first complimentary tumor cell immunotherapy medical insurance in China, with insurance amount up to a million
To further meet customers’ needs and help them better handle risks of high-incidence tumors, Ping An life launched the complimentary Ping An Cellular Immunotherapy (A) medical insurance (hereinafter referred to as "Cellular Immune A") on July 1. Relying on "high-amount medical insurance, cutting-edge medical technology, and refined medical services", Ping An Life created exclusive products for cellular immunotherapy to reduce patients’ pressure in medical consultations.
Fosun Kite Biotechnology Co., Ltd.’s Axicabtagene Ciloleucel Injection (hereinafter referred to as “Yescarta”) is China’s first cellular immunotherapy drug approved by the National Medical Products Administration. The drug treats non-Hodgkin lymphoma(NHL) cancer. As a high-incidence tumor, NHL shows an annual increase in patients. Although NHL has become curable with the development of medical technology, its easy relapse has become a clinical problem. Understanding customers’ needs, Ping An Life launched the exclusive Cellular Immune A complimentary insurance and built a strong safety net for customers by free medical insurance amount up to 1 million.
Yescarta is priced at more than two million RMB in the United States, and the price in China is about half of that in the US market. Ping An Life’s highest one million insurance amount for a year could well alleviate customers’ financial burden in seeking treatment.
After being launched on July 1, Cellular Immune A could be gained for free on Ping An Jin Guanjia App. If customers need to settle claim and are assessed as suitable for cellular immunotherapy treatment, they will be arranged to receive medical treatment in a designated medical institution. The reasonable and necessary medical expenses actually paid during the treatment period will be compensated for in accordance with the payment ratio agreed in the contract and relevant compensation rules.
There are many kinds of cellular immunotherapy, and the fastest developing one in the world is CAR-T therapy. On August 30, 2017, the US FDA approved Kymriah, the world's first CAR-T therapy drug. Up to now, five CAR-T therapy drugs including Kymriah, Yescarta, Tecartus, Breyanzi and Abecma have been approved by FDA in the United States. All five drugs have achieved good results in clinical treatment.
The principle of CAR-T therapy is called "directed biological cruise missile". Technicians use genetic engineering technology to activate T cells and install the positioning and navigation device CAR (Tumor Chimeric Antigen Receptor) to make CAR-T cells. After infusion, CAR-T specifically recognizes tumor cells in the body and can effectively kill them, thereby achieving the purpose of treating malignant tumors.
In order to solve customers’ difficulties in seeking medical treatment, Ping An Life has joined hands with the world-renowned medical assistance service provider Further to provide customers with full medical arrangement services including treatment plan evaluation, medical arrangement, and direct payment of drugs. If customers get unfortunately ill, they only need to report the case to Ping An Life. The follow-up tests, diagnosis and treatment, and payment of fees will be handled by a special person, so that customers can go to hospital without worries.
It is worth mentioning that for 6 consecutive months after the insured is diagnosed, there will be regular follow-up visits by Further’s general practitioners, who will pay close attention to the insured’s treatment, provide psychological counseling, and help establish a good mindset. If the insured meets the requirements for "patient assistance program" of relevant pharmaceutical companies, Further can also assist patients in applying.
Source: [JRJ.com](https://JRJ.com)
translation: InsurView
https://www.reddit.com/r/StockMarket/comments/oc4ydj/ping_an_life_launches_the_industrys_first/
